Janux Therapeutics, Inc.
JANX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,515,859 | $1,429,946 | $1,668,376 | $3,042,805 |
| - Cash | $48,389 | $52,446 | $73,743 | $430,605 |
| + Debt | $22,660 | $22,190 | $22,612 | $23,025 |
| Enterprise Value | $1,490,130 | $1,399,690 | $1,617,245 | $2,635,225 |
| Revenue | $10,000 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $9,499 | $0 | $0 | $0 |
| % Margin | 95% | – | – | – |
| EBITDA | -$23,812 | -$44,577 | -$34,378 | -$28,510 |
| % Margin | -238.1% | – | – | – |
| Net Income | -$24,313 | -$33,858 | -$23,508 | -$20,216 |
| % Margin | -243.1% | – | – | – |
| EPS Diluted | -0.39 | -0.55 | -0.38 | -0.36 |
| % Growth | 29.1% | -44.7% | -5.6% | – |
| Operating Cash Flow | -$12,856 | -$23,813 | -$17,024 | -$16,725 |
| Capital Expenditures | -$93 | -$473 | -$371 | -$42 |
| Free Cash Flow | -$12,949 | -$24,286 | -$17,395 | -$16,767 |